NAT1 and breast carcinoma: It has been reported that cisplatin can impair NAT1 by blocking its transferase activity in human breast cancer cells and impair murine Nat2 activity in cultured mouse tissues (liver and kidney) (29), which on one hand contributes to the therapeutic effects of cisplatin, but on the other hand may lead to accumulation of cisplatin in the kidneys.